

REIMBURSEMENT POLICY STATEMENT GEORGIA MARKETPLACE					
Policy Name		Policy Number		Effective Date	
Hepatitis Panel for Acute Viral Hepatitis		PY-1145		4/1/2020-12/31/2021	
Policy Type					
Medical	A	dministrative	Pharmacy	REIMBURSEMENT	

Reimbursement Policies prepared by CSMG Co. and its affiliates (including CareSource) are intended to provide a general reference regarding billing, coding and documentation guidelines. Coding methodology, regulatory requirements, industry-standard claims editing logic, benefits design and other factors are considered in developing Reimbursement Policies.

In addition to this Policy, Reimbursement of services is subject to member benefits and eligibility on the date of service, medical necessity, adherence to plan policies and procedures, claims editing logic, provider contractual agreement, and applicable referral, authorization, notification and utilization management guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any federal or state coverage mandate, Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

This Policy does not ensure an authorization or Reimbursement of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced herein. If there is a conflict between this Policy and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

CSMG Co. and its affiliates may use reasonable discretion in interpreting and applying this Policy to services provided in a particular case and may modify this Policy at any time.

Contents of Policy

<u>REIM</u>	BURSEMENT POLICY STATEMENT	1
<u>TABL</u>	E OF CONTENTS	1
<u>A.</u>	<u>SUBJECT</u>	2
<u>B.</u>	BACKGROUND	2
<u>C.</u>	DEFINITIONS	2
<u>D.</u>	POLICY	2
<u>E.</u>	CONDITIONS OF COVERAGE	3
<u>F.</u>	RELATED POLICIES/RULES	4
<u>G.</u>	REVIEW/REVISION HISTORY	4
<u>H.</u>	REFERENCES	4



Hepatitis F nel for Acute Viral Hepatitis

B. BACKGROUND

Reimbursement policies are designed to assist you when submitting claims to CareSource. They are routinely updated to promote accurate coding and policy clarification. These proprietary policies are not a guarantee of payment. Reimbursement for claims may be subject to limitations and/or qualifications. Reimbursement will be established based upon a review of the actual services provided to a member and will be determined when the claim is received for processing. Health care providers and their office staff are encouraged to use self-service channels to verify member's eligibility.

It is the responsibility of the submitting provider to submit the most accurate and appropriate CPT/HCPCS code(s) for the product or service that is being provided. The inclusion of a code in this policy does not imply any right to reimbursement or guarantee claims payment.

Acute viral hepatitis (AVH) is a systemic infection that mostly affects the liver. It can be caused by a virus, a toxin, or could be the beginning of chronic liver disease. The viruses that most often cause AVH are hepatitis A, B, C, D, and E. The typical symptoms are shown in all forms of AHV including jaundice, fatigue, abdominal pain, loss of appetite, nausea, diarrhea, fever, and dark urine.

C. DEFINITIONS

- Hepatitis panel: consists of the following tests:
 - Hepatitis A antibody (HAAb), IgM Antibody
 - Hepatitis B core antibody (HBcAb), IgM Antibody
 - Hepatitis B surface antigen (HBsAg)
 - o Hepatitis C antibody

D. POLICY

- I. Prior authorization is not required for hepatitis panel tests that are medically necessary.
 - **Note:** Although a Hepatitis panel does not require a prior authorization, CareSource may request documentation to support medical necessity. Appropriate and complete documentation must be presented at the time of review to validate medical necessity.
- II. Hepatitis panel is considered medically necessary when used for a differential diagnosis in members with **ANY** of the following:
 - A. Symptoms of hepatitis infection **OR**
 - B. Abnormal liver function tests **OR**
 - C. Before and after a liver transplantation.
- III. Hepatitis panel must be ordered and performed by a provider for these services, and when used in compliance with the Clinical Laboratory Improvement Act ("CLIA") regulations.





IV. Non-Covered Services

A. Once a diagnosis of hepatitis has been made, CareSource will not cover ongoing hepatitis panel testing. CareSource will cover, appropriate and medically necessary, individual hepatitis testing for its members.

E. CONDITIONS OF COVERAGE

CPT Codes Description

Reimbursement is dependent on, but not limited to, submitting Centers for Medicare & Medicaid Services (CMS) approved HCPCS and CPT codes along with appropriate modifiers. Please refer to the CMS fee schedule.

• The following list(s) of codes is provided as a reference. This list may not be all inclusive and is subject to updates. Please refer to the above referenced source for the most current coding information.

80074 Acute Hepatitis Panel Diagnosis Description Codes M25.50 Pain in unspecified joint			
Codes			
Codes			
M25.50 Pain in unspecified joint			
M79.10 Myalgia, unspecified site			
R10.0 Acute abdomen			
	Upper abdominal pain, unspecified		
R10.11 Right upper quadrant pain	Right upper quadrant pain		
R10.12 Left upper quadrant pain	Left upper quadrant pain		
R10.13 Epigastric pain	Epigastric pain		
R10.33 Periumbilical pain	Periumbilical pain		
R10.811 Right upper quadrant abdominal tenderness	Right upper quadrant abdominal tenderness		
0.821 Right upper quadrant rebound abdominal tendemess			
R10.83 Colic			
	Generalized abdominal pain		
R10.9 Unspecified abdominal pain	Unspecified abdominal pain		
R11.0 Nausea			
R11.10 Vomiting, unspecified			
R11.11 Vomiting without nausea	0		
R11.12 Projectile vomiting			
R11.14 Bilious vomiting			
R11.2 Nausea with vomiting, unspecified			
R17 Unspecified jaundice			
R19.5 Other fecal abnormalities (abnormal stool color)			
R50.9 Fever, Unspecified			
R53.1 Weakness			
R53.81 Other malaise			
R53.82 Chronic fatigue, unspecified			
R53.83 Other fatigue			



Simple febrile convulsions		
Complex febrile convulsions		
Post traumatic seizures		
Delayed milestone in childhood		
Unspecified lack of expected normal physiological		
Failure to thrive (child)		
Other lack of expected normal physiological development in		
Anorexia		
Polydipsia		
Polyphagia		
Feeding difficulties		
Abnormal weight loss		
.5 Abnormal weight gain		
Underweight		
Nonspecific elevation of levels of transaminase and lactic		
acid dehydrogenase [LDH]		
Abnormal levels of other serum enzymes		
.9 Abnormal serum enzyme level, unspecified		
98 Other abnormal findings in urine		
.5 Abnormal results of liver function studies		
Unspecified complication of liver transplant		
Liver transplant rejection		
Liver transplant failure		
Liver transplant infection		
Other complications of liver transplant		
Awaiting organ transplant status		
Z94.4 Liver transplant status		

F. RELATED POLICIES/RULES

G. REVIEW/REVISION HISTORY

7		DATE	ACTION	
	Date Issued	01/08/2020		
	Date Revised			
	Date Effective	04/01/2020	New policy	
	Date Archived		This Policy is no longer active and has been archived. Please note that there could be other Policies that may have some of the same rules incorporated and CareSource reserves the right to follow CMS/State/NCCI guidelines without a formal documented Policy.	

H. REFERENCES

1. National Coverage Determination (NCD) for Hepatitis Panel/Acute Hepatitis Panel (190.33). (2003, January 1). Retrieved November 21, 2019 from



24



Hepatitis Panel for Acute Viral Hepatitis GEORGIA MARKETPLACE PY-1145 Effective Date: 4/1/2020

https://www.cms.gov/medicare-coverage-database/details/ncddetails.aspx?NCDId=166&ncdver=1&CoverageSelection=Both&ArticleType=All&

PolicyType=Final&s=Ohio&KeyWord=hepatitis+panel&KeyWordLookUp=Title&KeyWordSearchType=And&bc=gAAAACAAAAA&

- 2. Centers for Medicare and Medicaid Services. Lab NCDs ICD-10. (n.d.). Retrieved November 21, 2019, from https://www.cms.gov/Medicare/Coverage/CoverageGenInfo/LabNCDsICD10
- World Gastroenterology Organisation Practice Guidelines: (2003, December). Retrieved November 21, 2019, from https://www.worldgastroenterology.org/UserFiles/file/guidelines/management-ofacute-viral-hepatitis-english-2003.pdf

The Reimbursement Policy Statement detailed above has received due consideration as defined in the Reimbursement Policy Statement Policy and is approved.

